AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- According to a study from the United States, "Tamoxifen is being used successfully to treat breast cancer. However, tamoxifen also increases the risk of developing endometrial cancer in postmenopausal women.
"Raloxifene also decreases breast cancer in women at high risk and may have a lower risk at developing cancer of the uterus."
Previous research conducted using rat liver cells has shown that tamoxifen stimulated release of arachidonic acid from these cells.
L. Levine of Brandeis University "postulated that arachidonic acid release from cells may be associated with cancer chemoprevention."
To pursue this, Levine labeled "rat liver, rat glial, human colon carcinoma, and human breast carcinoma cells . . . with [H-3] arachidonic acid. The release of the radiolabel from these cells during incubation with tamoxifen and the raloxifene analog LY117018 was measured. The prostaglandin I-2 produced during incubation of the rat liver cells with microM concentrations of tamoxifen and the raloxifene analog was quantitatively estimated."
The experiments showed "tamoxifen is about five times more effective than LY117018 at releasing arachidonic acid from all the cells tested."
"In rat liver cells only tamoxifen stimulates basal prostaglandin I-2 production and that induced by lactacystin and 12-O-tetradecanoyl-phorbol-13-acetate. LY117018, however, blocks the ...
Source: HighBeam Research, In vitro, arachidonic acid release may mediate tamoxifen, raloxifene...